LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.37
+0.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.0K | 36.0K | 61.0K | 130.0K | 84.7M |
| Cost of Revenue | 2.3M | 11.5M | — | — | — |
| Gross Profit | (2.3M) | (11.5M) | 61.0K | 130.0K | 84.7M |
| Operating Expenses | |||||
| R&D Expense | 156.5M | 158.7M | 171.6M | 182.9M | 159.2M |
| SG&A Expense | 40.4M | 45.1M | 52.0M | 67.0M | 117.3M |
| General & Admin Expense | 40.4M | 45.1M | 52.0M | 67.0M | 117.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (7.2M) | (11.5M) | 135.2M | (2.8M) | (4.8M) |
| Total Operating Expenses | 189.8M | 192.3M | 358.8M | 247.1M | 271.7M |
| Cost and Expenses | 192.1M | 203.8M | 358.8M | 247.1M | 271.7M |
| Operating Income (EBIT) | (192.1M) | (203.8M) | (358.8M) | (247.0M) | (187.1M) |
| Non-Operating | |||||
| Interest Income | 8.1M | 13.1M | 24.1M | 23.5M | 7.1M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 8.1M | 13.1M | 24.1M | 23.5M | 7.1M |
| Other Non-Op Income/Expense | (56.4M) | (70.7M) | 15.8M | 12.4M | 3.9M |
| Non-Operating Income (excl Interest) | 56.4M | 70.7M | (138.5M) | (12.4M) | (3.9M) |
| EBT (Pre-Tax Income) | (248.5M) | (274.4M) | (343.0M) | (234.6M) | (183.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (248.5M) | (274.4M) | (343.0M) | (234.6M) | (183.1M) |
| Earnings from Cont. Ops | (248.5M) | (274.4M) | (343.0M) | (234.6M) | (183.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (248.5M) | (274.4M) | (343.0M) | (234.6M) | (183.1M) |
| Per Share | |||||
| Basic EPS | ($16.01) | ($16.06) | ($1.31) | ($0.93) | ($0.74) |
| Diluted EPS | ($11.77) | ($16.06) | ($1.31) | ($0.93) | ($0.74) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.01 | $6.85 |
| Shares | |||||
| Basic Shares Outstanding | 23.4M | 17.1M | 13.1M | 12.5M | 12.4M |
| Diluted Shares Outstanding | 23.4M | 17.1M | 13.1M | 12.5M | 12.4M |
| Profitability Metrics | |||||
| EBITDA | (239.0M) | (262.9M) | (200.6M) | (214.4M) | (165.1M) |
| D&A | 9.5M | 11.5M | 19.6M | 20.3M | 18.0M |
| EBIT | (248.5M) | (274.4M) | (220.3M) | (234.6M) | (183.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026